Regarding the Initiation of New "Cedacure" Treatment in 2026

Cedacure, a medication used for the new initiation of sublingual immunotherapy for Japanese cedar pollen allergy, is currently subject to shipment restrictions by the manufacturer, Torii Pharmaceutical. Consequently, supplies at pharmacies remain limited. Our clinic intends to begin new treatments only when we have secured a sufficient supply of the medication.

Please inquire during your consultation about whether it is possible to start this new sublingual immunotherapy for Japanese cedar pollen allergy.

If a blood test confirms a positive reaction to Japanese cedar pollen and the treatment is deemed appropriate for you, we will add your name to our waiting list.

We will contact you in the order of the waiting list as soon as the medication arrives; once notified, please make an appointment to visit the clinic.

Please note that after the initial dose is administered, a 30-minute observation period within the clinic is required.

When booking the appointment for the initial dose, please select the option for "Initial Sublingual Immunotherapy" (Initial induction of sublingual immunotherapy) rather than "Follow-up Consultation" (Follow-up consultation) in the online booking system.

Please be aware that due to limited distribution, there may be a significant delay between being placed on the waiting list and actually starting the treatment.